Serum calcium-decreasing factor, caldecrin, ameliorates muscular dystrophy in dy/dy mice

In Vivo

Volumn 25, Issue 2, 2011, Pages 157-163

  Tomomura, Mineko ^a   Fujii, Takeru ^b   Sakagami, Hiroshi ^a   Tomomura, Akito ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^b Biodesign Ltd Tokushima   (Japan)

Author keywords

Calcium; Caldecrin; dy dy mice; Muscular dystrophy; Protease

Indexed keywords

CALDECRIN; CHYMOTRYPSIN; EVANS BLUE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME RELEASE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PARAINFLUENZA VIRUS 1; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL; VIRUS ENVELOPE;

EID: 79954989007     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. McArdle A and Jackson MJ: Intracellular mechanisms involved in skeletal muscle damage. In: Muscle Damage. Salmons S (ed.). Oxford: Oxford University Press., pp. 90-106, 1997.
2. Hoffman EP, Brown RH Jr. and Kunkel LM: Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928, 1987.
3. Ervasti JM and Campbell KP: Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121-1131, 1991.
4. Yoshida M and Ozawa E: Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 108: 748-752, 1990.
5. Straub V and Campbell KP: Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 10: 168-175, 1997.
6. Hoffman EP and Kunkel LM: Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 2: 1019-1029, 1989.
7. Matsumura K, Tomé FM, Collin H, Azibi K, Chaouch M, Kaplan JC, Fardeau M and Campbell KP: Deficiency of the 50k dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 359: 320-322, 1992.
8. Bönnemann CG., Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan DJ, Angelini C, Hoffman EP, Ozawa E and Kunkel LM: α- Sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genetics 11: 266-273, 1995.
9. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tomé FMS, Schwartz K, Fardeau M, Tryggvason K and Guicheney P: Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 11: 216-218, 1995.
10. Minners JM, Lacerda L, McCarthy J, Meiring JJ, Yellon DM and Sack MN: Ischemic and pharmacologic preconditioning in girardi cells and C2C12 myotubes induce mitochondrial uncoupling. Circ Res 89: 787-792, 2001. (Pubitemid 34633849)
11. Hirose L, Nosaka K, Newton M, Laveder A, Kano M, Peake J and Suzuki K: Changes in inflammatory mediators following eccentric exercise of the elbow flexors. Exerc Immunol Rev 10: 75-90, 2004.
12. McClung JM, Judge AR, Talbert EE and Powers SK: Calpain-1 is required for hydrogen peroxide-induced myotube atrophy. Am J Cell Physiol 296: C363-371, 2009.
13. Alderton JM and Steinhardt RA: Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. J Biol Chem 275: 9452-9460, 2000. (Pubitemid 30185173)
14. Bertorini TE, Bhattacharya SK, Palmieri GM, Chesney CM, Pifer D and Baker B: Muscle calcium and magnesium content in Duchenne muscular dystrophy. Neurology 32: 1088-1092, 1982. (Pubitemid 12029042)
15. Arahata K, Hayashi YK, Koga R, Goto K, Lee JH, Miyagoe Y, Ishii H, Tsukahara T, Takeda S, Woo M, Nonaka I, Matsuzaki T and Sugita H: Laminin in animal models for muscular dystrophy. Defect of laminin M in skeletal and cardiac muscles and peripheral nerve of the homozygous dystrophic dy/dy mice. Proc Japan Acad Ser B 69: 259-264, 1993.
16. Sunada Y, Bernier SM, Kozak CA, Yamada Y and Campbell KP: Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus. J Biol Chem 269: 13729-13732, 1994.
17. Xu H, Christmas P, Wu XR, Wewer UM and Engvall E: Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. Proc Natl Acad Sci USA 91: 5572-5576, 1994.
18. Williams DA, Head SI, Bakker AJ and Stephenson DG: Resting calcium concentrations in isolated skeletal muscle fibers of dystrophic mice. J Physiol 428: 243-256, 1990. (Pubitemid 20313655)
19. Takaoka Y, Takamori M, Ichinose M, Tsujihata M, Mori M, Eguchi K, MoriT, Hazama R and Ezaki K: A protein anabolic factor from porcine pancreas and its effects on mice and patients with progressive muscular dystrophy. IRCS J Med Sci 5: 103-105, 1977.
20. Takaoka Y and Hazama R: Perspective therapeutic agents for progressive muscular dystrophy. Saishinigaku 35: 999-1007, 1980 (in Japanese).
21. Matsumura T, Saito T, Nozaki S and Kang J: Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure. Rinsho Shinkeigaku 40: 439-445, 2000 (in Japanese).
22. Huang CC, Lin TJ, Lu YF, Chen CC, Huang CY and Lin WT: Protective effects of L-arginine supplementation against exhaustive exercise-induced oxidative stress in young rat tissues. Clin J Physiol 552: 306-315, 2009.
23. Tomomura A, Fukushige T, Noda T, Noikura T and Saheki T: Serum calcium-decreasing factor (caldecrin) from porcine pancreas has proteolytic activity which has no clear connection with the calcium decrease. FEBS Lett 301: 277-281, 1992.
24. Tomomura A, Tomomura M, Fukushige T, Akiyama M, Kubota N, Kumaki K, Nishii Y, Noikura T and Saheki T: Molecular cloning and expression of serum calcium-decreasing factor (caldecrin). J Biol Chem 270: 30315-30321, 1995. (Pubitemid 26006311)
25. Tomomura A, Akiyama M, Ito H, Yoshino I, Tomomura M, Nishii Y, Noikura T and Saheki T: Molecular cloning and expression of human caldecrin. FEBS Lett 386: 26-28, 1996. (Pubitemid 26144946)
26. Tomomura A, Yamada H, Fujimoto K, Inaba A and Katoh S: Determination of amino acid sequence responsible for suppression of bone resorption by serum calcium-decreasing factor (caldecrin). FEBS Lett 508: 454-458, 2001. (Pubitemid 33135490)
27. Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H and Tomomura A: Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity. J Biol Chem 285: 25448-25457, 2010.
28. Fujimoto K, Ohi M, Hasegawa H, Kanegae H, Inaba A, Tomomura M and Tomomura A: Inhibition of RANKL expression in synobial fibroblasts of rheumatoid arthritis by serum calcium-decreasing factor (caldecrin). J Meikai Dent Med 39: 42-51, 2010 (in Japanese).
29. Shimamura M, Morishita R, Endoh M, Oshima K, Aoki M, Waguri S, Uchiyama Y and Kaneda Y: HVJ-envelope vector for gene transfer into central nervous system. Biochem Biophys Res Commun 300: 464-471, 2003. (Pubitemid 38375832)
30. Hamer PW, McGeachie JM, Davies MJ and Grounds MD: Evans Blue Dye as an in vivo marker of myofiber damage: optimising parameters for detecting initial myofiber membrane permeability. J Anat 200: 69-79, 2002. (Pubitemid 34285290)
31. 2+ channel by the actin-binding proteins alpha-actinin and dystrophin. Am J Physiol Cell Physiol 282: C1502-1511, 2002.
32. 2+ in muscle. Am J Physiol Cell Physiol 288: C377-388, 2005.
33. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H and Gailly P: Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol 158: 1089-1096, 2002.
34. Gervásio OL, Whitehead NP, Yeung EW, Phillips WD and Allen DG: TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy. J Cell Sci 121: 2246-2255, 2008.
35. Lefkowitz DL and Lefkowitz SS: Fascioscapulohumeral muscular dystrophy: a progressive degenerative disease that responds to diltiazem. Med Hypotheses 65: 716-721, 2005. (Pubitemid 41021854)
36. Langenbach KJ and Rando TA: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 26: 644-653, 2002. (Pubitemid 35266088)
37. Bhatnagar S and Kumar A: Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med 88: 155-166, 2010.